AbbVie Inc.
METHODS OF ADMINISTERING ELAGOLIX

Last updated:

Abstract:

The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

Status:
Application
Type:

Utility

Filling date:

8 May 2020

Issue date:

27 Aug 2020